These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 15538550)

  • 1. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
    Rabasseda X
    Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
    Berk M; du Plessis AD; Birkett M; Richardt D
    Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of duloxetine on painful physical symptoms associated with depression.
    Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
    Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
    Schatzberg AF
    J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine pharmacology: profile of a dual monoamine modulator.
    Karpa KD; Cavanaugh JE; Lakoski JM
    CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
    Westanmo AD; Gayken J; Haight R
    Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
    Bech P; Kajdasz DK; Porsdal V
    Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a place for duloxetine?
    Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine: a new selective and dual-acting antidepressant.
    Bauer M; Möller HJ; Schneider E
    Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.
    Mariappan P; Ballantyne Z; N'Dow JM; Alhasso AA
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004742. PubMed ID: 16034945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful phase III study with serotonin-noradrenaline reuptake inhibitor. Soon a drug to control stress incontinence].
    MMW Fortschr Med; 2004 Feb; 146(7):59. PubMed ID: 15347056
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of urinary incontinence with Duloxetine.
    Basu M; Duckett J
    J Obstet Gynaecol; 2008 Feb; 28(2):166-9. PubMed ID: 18393011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
    J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review.
    Mariappan P; Alhasso A; Ballantyne Z; Grant A; N'Dow J
    Eur Urol; 2007 Jan; 51(1):67-74. PubMed ID: 17014950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine: a dual reuptake inhibitor.
    Dugan SE; Fuller MA
    Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of refractory hypochondriasis with duloxetine.
    Politi P; Emanuele E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1145-6. PubMed ID: 17493731
    [No Abstract]   [Full Text] [Related]  

  • 18. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
    Jost W; Marsalek P
    Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
    Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
    Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.